The future of value-based purchasing (VBP) is uncertain. Current models have theoretical promise, but critics point to minimal achievements. Despite the rhetoric around paying for value over volume, the percent of health care spending involved in pay-for-performance contracts has stagnated or declined. In addition, the polled enthusiasm among health care industry leaders for value-based purchasing is declining. […]
Washington, DC – Yesterday, Speaker Nancy Pelosi (D-CA), Majority Leader Steny Hoyer (D-MD), Energy & Commerce Committee Chairman Frank Pallone Jr. (D-NJ), Ways & Means Committee Chairman Richard Neal (D-MA), and Education & Labor Committee Chairman Bobby Scott (D-VA) released a joint statement announcing that H.R. 3, the Lower Drug Costs Now Act, will come to a floor vote next week. The National Coalition on Health Care supports H.R. 3 to lower prescription drug prices and urges its swift passage to the U.S. Senate. […]
Enough is enough–it is time for Congress to address rising insulin prices. Congress has failed to take any action to address the rising cost of insulin. However, the Protecting Access to Biosimilars Act of 2019, introduced by Rep. Diana DeGette (D-CO) in early April, is a promising first step to address the issue. The Energy […]
FACT SHEET Legislative solutions are needed to combat the rising cost of health care in the United States, which accounted for almost 18% of the GDP in 2017. One symptom of the problem, surprise medical bills, contributes to unpredictable, high out-of-pocket costs for consumers. Patients often encounter surprise medical bills when receiving emergency or ancillary […]
On February 28th, NCHC wrote a letter to the Senate HELP Committee addressed to Senator Alexander. The letter was in response to a request from Senator Alexander asking for policy recommendations to address the rising costs of health care. You can read the entire letter here.
On March 19, 2020, the National Coalition on Health Care (NCHC) sent a letter to Congress with policy recommendations that amplify the short- and long-term needs of those affected most by COVID-19. […]
The President’s proposal, while only a framework for Congress’ consideration, establishes the priorities of the Administration. NCHC is concerned that the priorities of the Administration do not serve public health and do not align with the mission of the Coalition. […]
Although we applaud the inclusion of CREATES Act in the final year-end spending package, which will help provide a boost to the generic drugs market, the end of the year package lacks any significant changes to drug policy that would protect Americans from the most expensive drugs. Americans have consistently indicated that high and increasing drug prices are the top concern, across both Democrats and Republicans. […]